KRYS logo

Krystal Biotech Inc. (KRYS)

$298.55

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on KRYS

Market cap

$8.85B

EPS

7.36

P/E ratio

41.6

Price to sales

22.28

Dividend yield

--

Beta

0.559296

Price on KRYS

Previous close

$297.90

Today's open

$299

Day's range

$295.06 - $299.88

52 week range

$202.99 - $382.54

Profile about KRYS

CEO

Krish S. Krishnan

Employees

295

Headquarters

Pittsburgh, PA

Exchange

Nasdaq Global Select

Shares outstanding

29633472

Issue type

Common Stock

KRYS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on KRYS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Krystal Biotech, Inc. - KRYS

NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Krystal Biotech, Inc. (“Krystal Biotech” or the “Company”) (NASDAQ: KRYS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

news source

GlobeNewsWire • 20 hours ago

news preview

Krystal Biotech to Present at Upcoming Investor Conferences

PITTSBURGH, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that management will take part in fireside chats and host investor meetings at the following conferences: Jefferies Global Healthcare Conference in London November 17, 2026 in London, England Fireside chat scheduled for 8:00 am GMT 9 th Annual Evercore Healthcare Conference December 1, 2026 in Coral Gables, Florida Fireside chat scheduled for 2:10 pm ET Citi's 2026 Global Healthcare Conference December 2, 2026 in Miami, Florida Fireside chat scheduled for 10:20 am ET Each presentation will be webcast live and may be accessed through a link on the Investors section of the Company's website . Archived versions of the webcasts will also be available on the Investors section of the Company's website for at least 30 days.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Krystal Biotech Q3 Earnings Call Highlights

Krystal Biotech NASDAQ: KRYS reported third-quarter 2026 revenue growth driven by continued adoption of its VYJUVEK treatment in the United States and international markets, while also outlining updated timelines for several clinical programs and authorizing a share repurchase program of up to $400 million.

news source

MarketBeat • Nov 2, 2026

news preview

Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 2, 2026

news preview

Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results

$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell carcinoma lesions in patients with Gorlin syndrome Strong balance sheet, ending the quarter with $1.2 billion in cash and investments Board authorizes share repurchase program of up to $400 million PITTSBURGH, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the third quarter ended September 30, 2026 and provided a business update. “Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline,” said Krish S.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Krystal Biotech Analyst Says Stock Weakness 'Overblown'

Krystal Biotech Inc. (NASDAQ:KRYS) stock is trading lower on Monday after the company provided a third-quarter update.

news source

Benzinga • Nov 2, 2026

news preview

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $2.66 per share a year ago.

news source

Zacks Investment Research • Nov 2, 2026

news preview

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 26, 2026

news preview

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, November 2, 2026, to discuss the financial results and provide a business update.

news source

GlobeNewsWire • Oct 22, 2026

news preview

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.

news source

Zacks Investment Research • Oct 16, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Krystal Biotech Inc.

Open an M1 investment account to buy and sell Krystal Biotech Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in KRYS on M1